Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
From the recent 10-K regarding Larson selling shares:
"The Plan may be earlier terminated upon (1) the date that Mr. Larson provides written notice to his broker of the termination of the Plan; (2) the completion of all sales contemplated by the Plan; (3) the conclusion of Mr. Larson or his broker, that the Plan, or the sales effected thereby, are not in compliance with Rule 10b5-1 or other applicable securities laws; (4) the death or legal incapacity of Mr. Larson, or (5) the occurrence of certain corporate events with respect to the Company specified in the Plan."
Darn, that bolded part couldn't be a protection against angry, fed up, misled and abused share holders, could it?
Come on Brent! Sell another 300,000 shares. Let's get the share price back under 1.50 to help your short friends. Brent Larson needs to be terminated and arrested.
I'm sure you're right BooDog...There's no better news than G D Brent Larson selling shares when many already suspect that he is feeding the shorts information to further damage the company and shareholder. If the company tried to sell him, they probably couldn't get a nickel.
If the NAVB share price is headed up, G D Brent Larson should be holding. Great job Brent! Announce your plans to sell shares when NAVB is finally back in the 1.70s...May a roofing hammer visit his skull, and the sooner THE BETTER! At least he didn't get to sell before Crede, THAT would be REALLY suspicious. LOL.
Don't look now, but NAVB is slowly trending up AND behaving like a stock that has 1,000 good possibilities in the works. Let's see if one of them can get the G D share price above 2.00 for more than a day.
The reduction in force that has been announced is music to my ears and I have posted many times in the past that layoffs ARE MORE THAN CALLED FOR. For too long, this company has been top heavy with executives earning well over $100K while the Crede deal and other huge missteps have crippled the stock and investor confidence in the company.
There is some talk of spinoff shares of MT for the Navidea shareholder. I expect a scenario like this:
MT starts with 80,000,000 shares. 50,000,000 of them will be sold on the open market as part of the IPO and the sale of these shares to the public will raise money for MT. The remaining 30,000,000 shares will be distributed to the NAVB shareholders in proportion to their relative positions AND WILL BE RESTRICTED STOCK THAT CANNOT BE SOLD FOR A MINIMUM OF 2 OR 3 YEARS. Since NAVB has 150,000,000 shares outstanding, it makes sense to award one spinoff share FOR EVERY FIVE NAVB SHARES OWNED. If someone owns 50,000 shares of NAVB, they would be awarded 10,000 spinoff shares of MT. If someone owns 4,000 shares of NAVB, they would be awarded 800 shares of MT.
Comment is invited. I do not believe for a second that the dividend shares in MT will be distributed in a better ratio than what I have said. My estimate is that 37.5% of INITIAL MT stock shares go to NAVB shareholders. We'll see.
How did the shorts cover more than 1.4 million shares in the second half of February? On February 24th the volume was 3,618,000 shares. Other than this day, the volume was under 613,900 shares for everyday of the second half of the month. It seems like the shorts found someone to sell them a huge chunk of shares at market (and right at the close)...
Will this continue for the next three months and our pps never see 3.50+ from short covering like it should?
Something tells me that more huge volume days in every 2 week period will be allowing substantial short covering. Unfortunate.
And where THE HELL is the next Manocept update? DDbuyer is really amazing, he is so soft spoken and patient...LOL.
NAVB has more down days than anything else, more excuses for failure than a rookie, and no regard for shareholders whatsoever. Where the hell is my roofing hammer?
1.54 tomorrow? Or am I being too optimistic?
Headed back to 1.40 and below yes we are...no buyers in sight. Maybe Brent Larson and his NAVB shorting friends can even drop the pps to 1.32 today. With this sham if a company, anything bad for the shareholder is not only possible, it's LIKELY.
Manocept isn't worth billions like Goldberg said.
I'm sure it's worth trillions. Where is a good cinder block when I need one?
Are they as durable as ever?
We have a quick return to low volume and disgusting stock performance. I actually expected different since our precious cash starved company will get $2 million up front from Norgine. To me, that is a lot of up front cash when one considers how little Navidea got for all of 2014 for Lymphoseek sales ($4.5 million).
The MT advisory board IS IN PLACE.
LET'S GET THE MT NEWS FLOWING RIGHT NOW GONZALEZ!
TOMORROW 3/10 WILL BE FINE.
Pathetic trading day following good news yesterday.
I smell new shorting today and possibly a rebound back toward 1.80 on Tuesday or Wednesday next week.
It's about G D time. Let's see what the shorts want to do. I never celebrate until there is an up closing price...
Great job Brent Larson!
NAVB pps falling with higher volume than we have seen for 2 weeks...What is the company going to announce tomorrow? That they wasted oceans of Lymphoseek again?
Where the HELL is my ROOFING HAMMER?!
The shorts seem to be holding their ammunition carefully right now. There is next to no volume, so with the pps standing still they have nothing to be afraid of in the here and now. There may be some covering happening, but it has to be minimal with this volume.
The next Macrophage PR could change all of that IF the company can finally do something right that is substantial. I'm really surprised that our volume has been below 500,000 shares for 7 out of the last 8 days - the only exception was the 3.6 million share day. Where are the buyers that took NAVB to 2.03 in late 2014?
It seems as if the shorts are waiting for the next news to pounce on (or for a day in advance of the news to start shorting and limit the rally).
In the here and now, buyers are no where in sight. Accordingly, the real battle is coming:
CAN THE COMPANY CONVINCE THE MARKET THAT MACROPHAGE THERAPUTICS IS WORTH A DAMN and WILL THE NEWS THAT THE COMPANY RELEASES REGARDING MACROPHAGE THERAPUTICS FINALLY BE ENOUGH TO TILT THE SCALE BACK IN FAVOR OF LONGS the way things were for much of 2012 and 2013 (until Crede)?
Let's see if NAVB stock can reach or surpass 1.74 today on this good news. Someone got the news early yesterday which now explains why we saw 1.67 yesterday.
THE TERMS OF THE 4694 and 5001 DEALS WILL BE KEY TO SHORT COVERING OR A LACK OF SHORT COVERING. MANOCEPT UPDATES WOULD ALSO BE MOST HELPFUL BUT ARE NO WHERE IN SIGHT!
The better the deal/s that the company is able to get, the more pressure the shorts will feel.
The further along Manocept is toward regulatory progess (and not just wasting money like Navidea is so good at), the more pressure the shorts will feel.
As it is, the shorts seem to be in absolutely no danger on 2/26/15.
An interesting analysis to consider is the total short covering over the most recently reported period compared to total volume for the same period. After all, our volume has been very low as of late. WHEN WE ARE SEEING HIGH SHORT COVERING WITH LOW VOLUME TRADING, THIS WILL BE A GOOD SIGN.
You're right. I'm sure 7.00+ is right on the horizon.
Maybe tomorrow we find out that the 3.2 million shares are the newest share offering from our beloved company to "raise much needed cash."
Where the hell is a Manocept update?
Where the hell is a deal on 4694 or 5001?
Why the hell is Brent Larson still on the payroll?
The company's ability to stall and simultaneously waste money is endless, but my patience is not.
How much money will the company EVER get back for 4694 and 5001 combined?
It damn well better be around $15 million OR MORE or we have all been had.
Simple, really.
Maybe tomorrow we find out that the 3.2 million shares are the newest share offering from our beloved company to "raise much needed cash."
Where the hell is a Manocept update?
Where the hell is a deal on 4694 or 5001?
Why the hell is Brent Larson still on the payroll?
Maybe tomorrow we find out that the 3.2 million shares are the newest share offering from our beloved company to "raise much needed cash."
Where the hell is a Manocept update?
Where the hell is a deal on 4694 or 5001?
Why the hell is Brent Larson still on the payroll?
Here's another number to keep an eye on ---------------> 1.63
A disgusting finish to a second week in a row that had news.
Ridiculously low volume - the shorts can knock NAVB down .10 at any moment.
How much further down does NAVB go this week? To 1.45? Will the company ever recoup a cent from 4694 or 5001? Millions of dollars of shareholder money have been invested in 4694 and 5001 and Gonzalez has nothing to report about the future of these assets. Maybe next month, maybe next month...As they delay more, more financial resources are wasted.
The way the company has been mismanaged for the past 18 months, they have far more detriments than assets - and it is pathetic.
NAVB is a tiresome shell game. Nothing more. Two PRs came out Monday and the pps is down from Monday even further. NAVB is a tiresome shell game. Nothing more...
NAVB stock continues to flounder near the 1.62 low since the MT announcement and Brent Larson continues to get paid $250K annually. What an insult to shareholders. Most longs love to defend the company. Unfortunately, company neglect of the shareholder and the share price are significant and deliberate oversights on the part of the company.
This PR is a new reason for worry and concern. Q4 revenues are likely under $1 million and there was probably another $500,000 in wasted Lymphoseek inventory. Revenue projections for 2015 are likely around $7 million at most. The company may state an expected revenue figure that is considerably higher, but will undoubtedly back peddle on it in June 2015 or September 2015 (further ruining the already weak share price OF COURSE). Maybe NAVB will be a 2016 story. Lol.
The company seems intent on getting the pps back to 1.25 or below. Looks like we go back there sooner than later. Since the PR detailing the news of the 2 new Lymphoseek sales people didn't destroy the pps, the company will abuse shareholders with both fists on Monday 2/9. Wonderful! Be sure to send Rick Gonzalez and Brent Larson a big thank you note for sticking it to loyal NAVB shareholders so early in 2015!
BooDog, I am a Navidea long (unfortunately for me). But you are right about one thing...I am VERY SHORT on patience with Gonzalez and company...and judging by the $2.5 million capital raise which amounts to little more than chicken shit, this stock is headed no where.
May the Navidea executive wives faces be slapped and slapped and slapped with a glass and bone chip whip until there is no skin left on their faces. 1.61 is disgusting. Wake up and realize how underperforming this company is. Maybe in 12 months when the stock is at 1.43 you'll wise up. And maybe a smart shareholder will deal with dipshit Brent Larson themselves...enough is enough. The two new Lymphoseek sales hires are proof enough to me that Q4 revenue will be NO WHERE NEAR $2 million. Let the executive wives facial beatings begin!
Palantir and BooDog - Be sure to send the company a thank you not for a job well done this week. We closed at 1.61 after a week with supposedly good news. Cinder block treatment is more than warranted here. Wake up!
The laugh is that you show up here more often to question my posts that are harshly critical of the company's BS rather than to offer anything of substance. Are you Brent Larson himself? Your 35 posts on ihub could easily never have appeared here and no one here would have given a damn.
Unless you are an NAVB short, you too should be mad as hell at the exceedingly poor performance of this stock coupled with the two new Lymphoseek hires. You too should be hoping that someone somewhere beats Larson and his wife's face apart with a roofing hammer.
It is amazing that no one has thrown Larson and his wife through a mulching machine. And it's even more amazing that you show up here when you do...
Holy F would I enjoy taking a cinder block to Brent Larson's G D skull.
We have more share price neglect on the part of the company and we still have a weak Q4 report right around the corner.
1.63...EFFING WONDERFUL!
Cave - Your analysis and points are often spot on with Navidea and appreciated by me. Seriously. Having said that though,
PLEASE DO NOT even hint at how simple this is MT valuation is to decode.
Navidea "valued" the company at 2.11 per share for the Crede deal AND WE ARE STILL NOT EVEN TRADING THERE WITH THIS MT FINANCING AND POTENTIAL THAT THE COMPANY SAYS MT HAS. Think about that...
The market does not seem to care about MT or the financing for it. At least, not yet.
$2.5 million is more than $1 million, but $2.5 million is nothing compared to $500 million. Point being - This .5% capital raise IS A START but absolutely nothing more.
Hope that helps.
Putting it another way, all of this talk about MT being worth $500 million simply because $2.5 million is .5% of $500 million is absolute nonsense. Some said that world annual world Lymphoseek sales would top $600 million. Look how that turned out. Who is coughing up the other $497.5 million to solidify the market cap?! No one that I know of, at least not yet. How stupid does the company think we all are?
The company needs to update investors and the market with solid data that proves MT is worth even $1. After all, RIGS was supposedly worth $3 billion and our stock is stuck under $2, thank you Brent Larson and Mark Pykett. Maybe they will spinoff MT into 39 distinct companies before it is all over (DDbuyer says at least 6 spin offs are possible). Regardless of how many spinoffs there are, they need to get someone at the financial helm who knows how to manage money and Brent Larson ain't the guy.
I don't think the market is viewing $2.5 million as significant enough to warrant serious new buying of NAVB shares. If a fund had thrown somewhere between $20 million and $100 million into Macrophage Theraputics for ownership of the subsidiary between 4% and 20% respectively (or even more), that would be far more significant. As it is, $2.5 million for .5% ownership of MT is just that - a measly $2.5 million. MT is worth the $2.5 million...not a cent more until additional investments are made or the market seems NAVB shares worth buying because Navidea owns MT. The Oldtimers seem to be in love with this capital raise as if it is sure fire proof that MT will be worth billions, and quickly. I like their optimism, but I don't share it presently.
We have a long way to go before this thing moves. And for all we know, the $2.5 million is just Crede deal money that hasn't been wasted yet on hiring more new Lymphoseek sales representatives. The initial capital to MT of $2.5 million is simply insignificant. Can this stock close above 2.00 ever again?
I'm getting mighty impatient over here...again!
Time for the company to retread my post here #7553. Can NAVB hold 1.62 if the company waits a decade to finally announce one of the long awaited f@@kng partnerships?
NAVB 1.85 Shorts hard at work?
Glad you can use the information...I remain eager to see today's short interest update. I think the shorts are why the stock hit 1.62 the day after Christmas. If so, their efforts that day were wasted. Tax loss selling may have been a factor as well, but NAVB rebounded quite well starting 12/29 through yesterday. Interest rates to borrow shares for shorting are up. I have no doubt the short interest is up as well.
GLTA.
Shrekeli helped to damage the NEOP (now NAVB) share price back in May-June 2011 when the stock soared into the 4.50-5.40 range. He was never held accountable for any of the false information and ridiculous rumors he spread to help damage the share price. Even now, shorts continue to whack away at our stock price, though doing so now seems unwise. Shorting at 5.00+ was obviously a smart trade if one covered even at 3.00.
AND SPEAKING OF SHORTS, tomorrow we should get another short interest update. Is anyone besides me expecting an increase of somewhere between 1,000,000 and 2,000,000 shares? The interesting thing about tomorrow's report is that it will cover 12/16-12/31 and this is the time period immediately following the 12/15 Manocept announcement. NAVB got down to 1.62 the day after Christmas. Let's see what's in the numbers. Should be interesting and telling.
GLTA.
You can compare me with other posters or call me any names you want to. The fact of the matter is, the company has lost some investor confidence with their uncontrolled spending over the past three years and the Crede deal. I am surprised and pleased that the stock rebounds intraday from prices like 1.82 back to 1.89. Even so, this company still has much to prove given the harm they have carelessly done to shareholders and I'll continue to feel more than welcome to speak up when I think the company needs an ear screaming. Rumor is, Brent Larson has 15% hearing loss following our June 2014 phone call.
It's really too bad that Navidea didn't hire 75 new people at $100k annually to sell Lymphoseek. If the company had done so, they could have got the share price back under 1.00 in no time. As it is, with two or three more weeks of no news, the lousy Q4 report we have to look forward to should do it.
No one should forget that the company lowered Lymphoseek revenue guidance to $4 million for 2014. Shareholder value seems to be a fleeting interest of the company yet again. The longer the company farks around before the next Manocept update, the worse it is going to get.
Brent Larson needs to be terminated. He is not up to managing the finances of this company, especially if Manocept is going somewhere. He will deliberately harm the company like he has done for years.
Absolutely right.